Table of Content - Central Precocious Puberty Market

Gonadotropin-releasing hormone (GnRH) agonist are potential treatment options for the CPP as they inhibit stimulation effects of endogenous GnRH and accelerate bone maturation, thereby suppressing early puberty. GnRH therapy delays the onset of puberty leading to delay in menarche Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are approved treatment medications available in the market for central precocious puberty (CPP). Moreover, Triptodur, Lupron Depot-Ped, and Supprelin LA are Gonadotropin-releasing hormone (GnRH) agonists used to prolong the suppression of gonadotropin secretion when required. Triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children with CPP.

Market Dynamics

Reimbursement for the treatment of central precocious puberty is provided through Medicaid, which is expected to offer lucrative growth opportunities for the global central precocious puberty market during the forecast period. According to N.C. Medicaid Bulletin December 2017, Triptodur: an extended-release injectable suspension for intramuscular use, operates under Medicaid Healthcare Common Procedure Coding System (HCPCS) code J3490. According to the same source, from September 2017, N.C. Medicaid and N.C. Health Choice (NCHC) programs cover triptorelin extended-release injectable suspension for intramuscular use (Triptodur) for use in the Physician's Drug Program (PDP). For Medicaid and NCHC billing, the maximum reimbursement rate per unit of Triptodur is: US$ 17,280.00 per kit.

Key features of the study

This report provides an in-depth analysis of the global central precocious puberty market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this marke
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global central precocious puberty market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global central precocious puberty market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central precocious puberty market

Market Segmentation

By Drug (Revenue, USD Mn, 2021-2033)
- Leuprolide Acetate
- Triptorelin
- Histrelin Acetate
- Nafarelin
By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Central Precocious Puberty Market, By Region (Revenue, USD Mn, 2021-2033)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa
Key Players
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Arbor Pharmaceuticals, LLC
- Pfizer Inc.
- Tolmar Pharmaceuticals, Inc.
- Endo International plc
- Ipsen Pharma
- Debiopharm Group
- Sun Pharmaceutical Industries Limited

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drug
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter’s Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
Global Central Precocious Puberty Market, By Drug, 2021 – 2033, (USD Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022– 2033
  - Segment Trends
- Leuprolide Acetate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
- Triptorelin
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
- Histrelin Acetate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
- Nafarelin
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
Global Central Precocious Puberty Market, By Distribution Channel, 2021 – 2033, (USD Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 – 2033
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
Global Central Precocious Puberty Market, By Region, 2021 – 2033, (USD Mn)
- Introduction
  - Market Share Analysis, By Region, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, For Regions, 2022–2033
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
  - Teva Pharmaceutical Industries Ltd.
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - AbbVie Inc.
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Arbor Pharmaceuticals, LLC
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Pfizer Inc.
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Tolmar Pharmaceuticals, Inc.
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Endo International plc
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Ipsen Pharma
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Debiopharm Group
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Sun Pharmaceutical Industries Limited
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
- Analyst Views
Section
- References
- Research Methodology
- About Us

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now